

R H I N O M E D

RHINOMED EXPANDS US DISTRIBUTION WITH MAJOR AMERICAN HEALTHCARE COMPANY

February 5th, 2018. Melbourne, Australia.

Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise it has entered into a Wholesale Purchase and Distribution Agreement with global healthcare company Cardinal Health.

Under the agreement, all four pack variants of the company's 'Mute' sleep and snoring technology will be available for ordering by Cardinal Health's extensive network of independent pharmacies in the US market. Cardinal Health currently supplies more than 25,000 retail pharmacies¹ across the USA.

This agreement builds on Rhinomed's strong store growth in the US market over the last 12 months and is reflective of Mute's growing brand awareness in the USA.

Mute is an over-the-counter product that snoring by helping improve airflow through the nose. Mute is designed to fit the natural anatomy of the nose and it is fully adjustable so you can control the level of dilation and airflow for a comfortable fit.

Media Enquiries

Michael Johnson, CEO & Director
+61 (0) 3 8416 0900
mjohnson@rhinomed.global
www.mutesnoring.com

Follow us on **Twitter** @rhinomedceo and @mutesnoring

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global

Source: <http://ir.cardinalhealth.com/Home/default.aspx>

1 <http://ir.cardinalhealth.com/investor-resources/cah-at-a-glance/default.aspx>

For personal use only